N-[3-[1-[2-羟基-4-氧代-6-(2-苯基乙基)-6-丙基-5H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)吡啶-2-磺酰胺 | 174484-81-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 中文名称: N-[3-[1-[2-羟基-4-氧代-6-(2-苯基乙基)-6-丙基-5H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)吡啶-2-磺酰胺
• 中文别名: 1-丙酮,2-氨基-1-(2-羟基苯基)-
• 英文名称: N-[3-[1-(5,6-Dihydro-4-hydroxy-2-oxo-6-propyl-6-phenethyl-2H-pyran-3-yl)propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
• 英文别名: 2-Pyridinesulfonamide, N-(3-(1-(5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-；N-[3-[1-[4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
• CAS: 174484-81-2
• 化学式: C₃₁H₃₃F₃N₂O₅S
• 分子量: 602.675
• InChiKey: SUJUHGSWHZTSEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Process for the synthesis of an antiviral compound
  申请人：Honeywell International, Inc.

  公开号：US20040110957A1

  公开（公告）日：2004-06-10

  In a process comprising synthesizing pyranes including [R—(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide the present invention comprises the improvements comprising: (a) providing a racemic mixture of 3-hydroxy-3-(2-phenylethyl)-hexanoate ethyl acetate by reacting said 1-phenyl-hexan-3-one with ethylbromoacetate under Reformatsky conditions; and (b) separating (R)-3-hydroxy-3-(2-phenylethyl)-hexanoic acid in enantiomeric excess by saponification and reverse resolution of the racemate of step (a) to produce a resolved product. In addition, the present invention comprises a reverse resolution process for separating an enantiomer from a mixture of enantiomers.

  本发明涉及合成吡喃类化合物的方法，包括合成 [R—(R*,R*)]-N-[3-[1-[5,6-二氢-4-羟基-2-氧代-6-(2-苯乙基)-6-丙基-2H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)-2-吡啶磺酰胺的改进。所述改进包括：(a)通过在Reformatsky条件下将1-苯基己酮与溴乙酸乙酯反应，提供3-羟基-3-(2-苯乙基)己酸乙酯的外消旋体混合物；(b)通过皂化和反向分离步骤(a)的外消旋体，分离出(R)-3-羟基-3-(2-苯乙基)己酸，以产生一个分离的产物。此外，本发明还涉及从对映体混合物中分离对映体的反向分离方法。
• Oligomer-Protease Inhibitor Conjugates
  申请人：Riggs-Sauthier Jennifer

  公开号：US20110269677A1

  公开（公告）日：2011-11-03

  The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.

  该发明提供了通过共价连接水溶性寡聚体进行化学修饰的蛋白酶抑制剂。该发明的结合物在通过任何一种给药途径进行给药时，表现出与未连接水溶性寡聚体的蛋白酶抑制剂不同的特性。
• Protease Inhibitors
  申请人：Riggs-Sauthier Jennifer

  公开号：US20120108501A1

  公开（公告）日：2012-05-03

  The invention relates to (among other things) protease inhibitors containing both a water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over protease inhibitor compounds lacking the water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue.

  本发明涉及含有水溶性非肽寡聚体和含有亲脂性基团残基的蛋白酶抑制剂（除其他外）。本发明的化合物在通过多种给药途径任何一种给予时，比缺乏水溶性非肽寡聚体和含有亲脂性基团残基的蛋白酶抑制剂化合物具有优点。
• OLIGOMER-PROTEASE INHIBITOR CONJUGATES
  申请人：NEKTAR THERAPEUTICS

  公开号：US20140045770A1

  公开（公告）日：2014-02-13

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.

  本发明提供了通过共价结合水溶性寡聚物进行化学修饰的小分子药物。本发明的结合物在通过任何一种给药途径给予时，表现出与未连接水溶性寡聚物的小分子药物不同的特性。
• Method for improving the pharmacokinetics of tipranavir
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1712231A2

  公开（公告）日：2006-10-18

  The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.

  本发明涉及一种改善替拉拉韦药代动力学的新方法，包括给需要这种治疗的人服用治疗有效量的替拉拉韦或其药学上可接受的盐和治疗有效量的利托那韦或其药学上可接受的盐的组合。